Intercept Pharmaceuticals, which recently submitted a marketing application to the European Medicines Agency for obeticholic acid, believes the product has the potential to become an essential treatment for people living with advanced fibrosis due to nonalcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease.
Intercept is among several companies in the race to market a drug for NASH in the industrialized world; the company...








